C. K. Wang, Chief Executive Officer of COTA, shared a post by COTA, adding:
“I’m incredibly proud to share that, today, COTA and Verana Health are joining forces in a merger that brings together two organizations deeply committed to improving how real-world data accelerates research, informs care, and ultimately benefits patients.
Throughout my career as an oncologist, I’ve needed to treat patients and address clinical scenarios not studied in clinical trials. High-quality real-world data matters because it can help to close that gap. It can give researchers better signals, clinicians better context, and lead to care that better matches what patients experience in the real-world.
At COTA, our work has focused on building oncology data that captures clinical depth and nuance and can stand up to rigorous research and regulatory use. Verana Health brings a complementary approach through clinician-led registries and technology that turns real-world specialty care data into disease-specific, research-ready insights across multiple therapeutic areas.
Together, we are expanding what is possible by building a broader evidence foundation with stronger clinical context and fewer barriers between questions and answers. This combination allows researchers, regulators, and care teams to move with greater confidence and speed, while keeping the patient experience at the center of the work.
I’m grateful to the teams at COTA and Verana Health who made this partnership possible, and I’m confident in what we can build together to advance care for patients.
And to all of our trusted partners and collaborators…I’m excited for all that we can accomplish together in 2026.”
“We’re proud to announce that Verana Health and COTA have officially merged.
With its focus on real-world patient data in oncology, COTA complements Verana Health data and technology offerings across ophthalmology, urology, and neurology. This partnership brings together two organizations with a shared commitment to deliver deeper, more clinically rich real-world data and insights that support life sciences companies with clinical trials, drug submissions, health economics research, market-access strategies, and clinicians with MIPS advisory services.
We’re grateful to our teams, partners, and customers who made this milestone possible.
Learn more here.”